Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCK-276 in rheumatoid arthritis
NCT05437419Phase 1Completed
- Sponsor
- Teijin
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TCK-276 in rheumatoid arthritis (RA) (4 cohorts), sponsored by Teijin. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 42 days. Started Aug 2022; status: completed.
02
Drugs
TCK-276
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05437419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437419.